Abstract
Angiotensin II is the main effector molecule of the renin-angiotensin system and has been implicated in regulating cell growth, inflammation and fibrosis, contributing to cardiac remodeling, growth and apoptosis. Cardiac remodeling is the determinant in the progression of heart failure. Thus, chronic activation of the renin-angiotensin system plays an important role in the structural and functional pathogeneses of heart failure. To date, most of the known physiological effects of Ang II in adult tissues are attributable to the AT1R although recent progress has shown some important actions of the involvement of AT2R. Clinical trials have documented consistent mortality and morbidity benefits of angiotensin receptor blockers in patients with chronic heart failure. Recent experimental studies link the beneficial effects of inhibiting Ang II to transforming growth factor-β1. Extracellular matrix accumulation in cardiovascular system is involved in vascular and cardiac hypertrophy and heart failure. Therefore, Ang II and TGF-β1 cross talk provides the pathophysiological insight in the development of cardiac fibrosis and heart failure. These molecular interactions might provide the beneficial effects of chronic AT1 receptor blockade, a known antifibrotic strategy, in patient with heart failure.
Keywords: Angiotensin II, cardiac remodeling, heart failure, transforming growth factor β1, angiotensin II receptor blockers
Current Cardiology Reviews
Title: Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Volume: 3 Issue: 4
Author(s): Hadyanto Lim and Zhu Yi Zhun
Affiliation:
Keywords: Angiotensin II, cardiac remodeling, heart failure, transforming growth factor β1, angiotensin II receptor blockers
Abstract: Angiotensin II is the main effector molecule of the renin-angiotensin system and has been implicated in regulating cell growth, inflammation and fibrosis, contributing to cardiac remodeling, growth and apoptosis. Cardiac remodeling is the determinant in the progression of heart failure. Thus, chronic activation of the renin-angiotensin system plays an important role in the structural and functional pathogeneses of heart failure. To date, most of the known physiological effects of Ang II in adult tissues are attributable to the AT1R although recent progress has shown some important actions of the involvement of AT2R. Clinical trials have documented consistent mortality and morbidity benefits of angiotensin receptor blockers in patients with chronic heart failure. Recent experimental studies link the beneficial effects of inhibiting Ang II to transforming growth factor-β1. Extracellular matrix accumulation in cardiovascular system is involved in vascular and cardiac hypertrophy and heart failure. Therefore, Ang II and TGF-β1 cross talk provides the pathophysiological insight in the development of cardiac fibrosis and heart failure. These molecular interactions might provide the beneficial effects of chronic AT1 receptor blockade, a known antifibrotic strategy, in patient with heart failure.
Export Options
About this article
Cite this article as:
Lim Hadyanto and Zhun Yi Zhu, Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms, Current Cardiology Reviews 2007; 3 (4) . https://dx.doi.org/10.2174/157340307782418370
DOI https://dx.doi.org/10.2174/157340307782418370 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke
Cardiovascular & Hematological Agents in Medicinal Chemistry Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism Use of Recombinant Human Erythropoietin as an Antianemic and Performance Enhancing Drug
Current Pharmaceutical Biotechnology Sympathetic Overactivity in Patients with Chronic Renal Failure - The Culprit of Increased Cardiovascular Mortality?
Current Hypertension Reviews Mesenchymal Stem Cells in Cartilage Regeneration
Current Stem Cell Research & Therapy Role of Nuclear Steroid Receptors in Apoptosis
Current Medicinal Chemistry A Multidisciplinary Atrial Fibrillation Clinic
Current Cardiology Reviews Anti-Inflammatory and Anti-Neoplastic Actions of Resveratrol
Current Nutrition & Food Science The Potential of Secondary Metabolites from Plants as Drugs or Leads Against Protozoan Neglected Diseases - Part II
Current Medicinal Chemistry Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Current Molecular Medicine Post-Wortmannin Era: Novel Phosphoinositide 3-Kinase Inhibitors with Potential Therapeutic Applications
Current Enzyme Inhibition Levosimendan for Perioperative Cardioprotection: Myth or Reality?
Current Cardiology Reviews Allosteric Drugs and Seven Transmembrane Receptors
Current Topics in Medicinal Chemistry Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Effects of Diabetes on Murine Lipoproteins and Vascular Disease
Current Drug Targets Medicinal Chemistry and Therapeutic Potential of Agonists, Antagonists and Allosteric Modulators of A1 Adenosine Receptor: Current Status and Perspectives
Current Pharmaceutical Design Editorial: Thematic Issue-Topic–Diabetic Cardiovascular Disease–An Unmet Medical Need: Emerging Targets and Therapies-Introduction to the Special Issue
Cardiovascular & Hematological Agents in Medicinal Chemistry